Autoimmunity of Gastrointestinal Tract by Pituch-Noworolska, Anna & Mach-Tomalska, Monika
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 5
Autoimmunity of Gastrointestinal Tract
Anna Pituch-Noworolska and
Monika Mach-Tomalska
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/67281
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited. 
Anna Pituch-Noworolska and Monika 
Mach-Tomalska
Additional information is available at the end of the chapter
Abstract
Gastrointestinal tract diseases are recognised as autoimmune based on typical histopa-
thology, presence of autoantibodies in serum and clinical response to immunosuppressive 
therapy. Like in other autoimmune diseases, the inducing factor is unknown; however, 
accumulating data suggests an increasing role of microbiota homeostasis and relation 
between the immune system (mucous-associated lymphoid tissue) and microbiota in 
intestinal lumen. The inflammation process is now described as autoinflammation with 
inflammasome formation or autoimmune chronic inflammation with overproduction of 
pro-inflammatory cytokines. Diagnostic procedures include autoantibodies assay, histol-
ogy of biopsy from intestinal mucous, genetic background (especially in celiac disease) 
and clinical symptoms. Therapy is adjusted to pathomechanism including regulation of 
microbiota homeostasis with pre-biotics and probiotics, inhibition of inflammatory pro-
cess with steroids, classical immunosuppression and anti-cytokine monoclonal antibod-
ies and haematopoietic stem cells transplantation in severe cases with therapy resistance, 
progression and life-threatening course. The aim of this chapter is to review mechanisms 
of autoinflammation and autoimmunity, diagnosis and therapy of gastrointestinal tract.
Keywords: autoimmunity, autoinflammation, microbiota homeostasis, pro-inflammatory 
cytokines, autoantibodies, immunosuppression, monoclonal antibodies
1. Introduction
Autoimmunity is the aberrant reaction of specific immune system to autoantigens. The stimuli 
leading to recognition of own determinants, receptors, cell products as antigens, followed by 
activation of T and B lymphocytes are unknown. The genetic background is described in few 
diseases from a long list of autoimmune syndromes. This aberrant reaction of immune system is 
irreversible, so the diagnosis of autoimmune process makes it lifelong one. The criteria of auto-
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immune process include tissue infiltration with immunocompetent cells, overproduction of pro-
inflammatory cytokines, and production of autoantibodies by plasmocytes. This process is going 
for years before clinical manifestation as an effect of non-reparable tissue damage. Autoimmune 
diseases are classified as systemic or organ-specific, based on origin of autoantigen and involved 
organs being the target for autoantibodies and deposits of immune complexes binding and acti-
vating complement cascade. The presence of autoantibodies in serum is one of the laboratory 
criteria for the ongoing autoimmune process; moreover, the precise description of the type and 
amount of autoantibodies suggests the type of disease. The aim of this chapter is to review mech-
anisms of autoinflammation and autoimmunity, diagnosis and therapy of gastrointestinal tract.
2. Physiology of gastrointestinal tract mucous membrane
2.1. The role of microbiota
In our intestinal lumen exists about 1014 commensal organisms is in symbiotic relation with the 
host. The interaction of microbiota and intestinal immune system including innate and adoptive 
immune mechanisms is bidirectional—microorganisms are influencing activity of cells present 
in epithelial cell monolayer and activity of immune cells is regulating commensal microbiota 
compound, localization and attachment to epithelial cells [1, 2]. The newborn babies acquire the 
microbiota during vaginal birth. It is obvious that caesarean section obviates contact with vaginal 
microenvironment and that resulted in differences of microbiota. The colonization of intestine at 
birth affects innate and adaptive immune system associated with mucous membrane of gut [3]. 
The response of immune system differentiating between commensal and invasive pathogens is 
not fully elucidated yet. The role of toll-like receptors (TLR), especially TLR5 for bacterial flagel-
lin, is described based on inflammation in deficiency of this receptor. TRLs are pathogen recogni-
tion sensors detecting bacterias, viruses and fungi. Stimulation of TLRs and NOD-like receptors 
(NLRs) leads to the production of pro-inflammatory cytokines and formation of protein com-
plex called inflammasome. NLRs are the group of intra-cellular pattern recognitions receptors 
(PRRs) involved in the recognition of many DAMPs and PAPMs (danger and pathogen-associ-
ated molecular patterns) in commensal and pathogenic microbiota. Inflammasome is a crucial 
structure for defence to pathogens but, from the other perspective, is involved in pathogenesis 
of autoinflammatory and autoimmune diseases following the prolonged inflammatory process 
[4–6]. The forming of inflammasome is not the only way of interaction between microbiota and 
immune systems. Another is based on influence of bacterial metabolites and its components such 
as fatty acids on epithelial cells inducing production of antimicrobial peptides (AMP). Stimulated 
epithelial cells produce IL-25 directly reacting with myeloid cells present in mucous. The cascade 
of activation resulted in stimulation of ILC3 subpopulation of immune system and production 
of cytokines [5].
2.2. The immune system of mucous membrane
The mucous membrane is one of our defence mechanisms against pathogenic microorganism 
intake with food into intestinal lumen. Its basic role is to regulate the response of immune 
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system to pathogens and the homeostasis of commensal microbiota. The epithelial layer con-
sists of different cells like epithelial cells, M cells, Paneth cells and goblet cells with specific 
function of mucous production. There are differences of stages of in situ maturating along 
transposition from crypts to the surface of epithelial layer. Moreover, some observations sug-
gest the cross-talk between epithelial cells and commensal microbiota facilitating to maintain 
homeostasis and to improve response to infectious pathogens. Paneth cells are localized close 
to crypts in the villi of small intestine. The expression of MyD88 molecule is important for 
TLR-MyD88-dependent pathway of microbiota recognition. Stimulation of this way results 
in the production of antimicrobial factors such as defensin, CRP-ductin, RegIII-γ and oth-
ers to protect the optimal environment for crypts’ stem cells. The goblet cells are also regu-
lated partially through TLRs. The main role of goblet cells is production of mucins inhibiting 
the attachment of bacterial (commensal or pathogenic) to epithelial cells layer, particularly 
mucin-2, a main colonic gel-forming one [5]. The role of M cells is based on uptake of anti-
gens from luminal spaces and induction of antigen-specific immune response. Their localiza-
tion in the follicles-associated epithelia of Payer’s patches and/or isolated lymphoid follicles 
facilitates the induction of antigen-specific immune response within the mucous membrane. 
The last study showed that M cells are the entry point for intra-tissues commensal flora 
inducing IgA production in Peyer’s patches [5, 7]. The last equally important cells from epi-
thelial layer are columnar epithelial cells forming very tight monolayer surface barrier, being 
regulated by the commensal microbiota. The role of bridge between the innate and adaptive 
immune systems in mucous membrane plays interleukin 23 (IL-23). The axis IL-23/IL-17 is 
important for IL-17 producing cells-Th17 subpopulation of T lymphocytes. In mucosal sites, 
the cell populations consist of T lymphocytes derived mainly from TCRγ/δ subpopulation, 
Th17 lymphocytes, mature T lymphocytes TCRα/β (CD3/CD4, CD3/CD8) and dendritic cells, 
NK cells. IL-23 induces cytokines production by innate lymphoid cells (ILCs) discovered 
in the mucous system. ILCs belong to three different types—group 1: ILC1 and NK cells 
producing IFN-γ, group 2: ILC2 natural helper cells expressing retinoid acid receptor (RAR) 
and group 3: ILC3 including foetal lymphoid tissue inducer cells, subpopulation of NK cells 
(NK22, NKp46 positive/negative). ILCs produce IL-17A, IL-17F or IL-22. These groups differ 
in expression of receptors and, in consequence, play different regulatory roles in maintain-
ing the homeostasis, induction of immune system response and inflammatory process [4, 5]. 
Th17 lymphocytes, localized in lamina propria, produce large amounts of cytokines: IL-17A, 
IL-17F, IL-21 and IL-22 after stimulation with IL-6 and TGF-β. Increased expression of IL-23 
receptor on Th17 lymphocytes induces positive autoregulatory feedback loop. Cytokines 
produced by Th17 clear microbes reaching lamina propria, maintain tightness of mucous 
barrier [2]. This subpopulation of T lymphocytes is very important in induction of inflam-
mation, so the regulation of functions inhibits or induces this process. Moreover, within T 
lymphocytes was described small subpopulation with phenotype CD3/CD4/CD25 and FoxP3 
called T regulatory cell with main function of regulation and control of the autoimmune 
process. Those Tregs are main producers of anti-inflammatory cytokines—IL-10 and TGF-β 
balancing pro-inflammatory derived activation of cells [2, 4, 5, 7]. The low number or dys-
function of these cells facilitates autoimmunity development. Those, depletion of Treg may 
explain the high frequency of autoimmune diseases among patients with humoral immunity 
deficiencies.
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2.3. The role of IgA
Dimeric, secretory IgA (sIgA) is produced locally by B cells and plasma cells present in 
lamina propria, isolated lymphoid follicles (ILF) and subepithelial dome (SED) of Peyer’s 
patches in intestine wall. The J chain (joining chain) responsible for the dimeric structure of 
IgA contributes in binding of IgA to polymeric immunoglobulin receptor (pIgR) facilitat-
ing the transport through epithelial cells and release into intestinal lumen. The data about 
the role of sIgA systematically increase based on clinical symptoms and disturbances of 
gut microbiota homeostasis in patients with isolated IgA deficiency when IgG and IgM are 
replacing sIgA. Now, the sIgA role is well known. Molecules of sIgA bind to pathogens and 
block the attachment to epithelial cells and invasion into intestinal tissue. This activity of 
sIgA, called immunological exclusion, is very effective in defence of epithelial cells during 
the mucosal infections [8]. Moreover, IgA facilitates contact of the different particles from 
intestinal lumen with dendritic cells localized in SED of Peyer’s patches. IgA also plays a 
regulating role for commensal microbiota with large fraction coated with IgA in normal, 
homeostatic conditions [8]. Plasmablast-producing IgA is generated locally in GALT from 
naïve B cell, mainly in Peyer’s patches. IgA plasmablast migrates into intestinal lamina pro-
pria and maturates into IgA-antibody secreting cells (IgA-ASC) along this way. The regu-
lation of this migration is based on the combination of cytokines and adhesion molecules 
expression e.g. CCR9 and CCR10—mucosa-specific chemokine receptors on IgA-ASC. The 
expression of ligands for these receptors showed different patterns depending on localization 
in intestine—jejunum or large bowel. Moreover, the types of antigens and their stimulation 
of IgA production are important for regulating IgA-dependent response in different parts 
of intestine. IgA production and maturation of plasmablasts are regulated by T cell–derived 
cytokines. T lymphocytes are involved in the formation of germinal centres and generation 
of IgA producing cells through, e.g., induction of activation-induced cytidine deaminase 
(AID) expression in B lymphocytes. This enzyme is critical for the process of a class switch 
recombination and hypermutation leading to production of IgA. Subpopulations of T cells—
Th17 and Treg cells—play the special regulatory role for IgA transport through induction of 
expression of polymeric immunoglobulin (pIgR) receptor on epithelial cells. In promotion of 
IgA-producing cells, the following cytokines T lymphocytes-derived are involved—TGF-β, 
IL-4, IL-10 and IL-21. TGF-β acts on B lymphocytes as a promoter of naïve B cell proliferation 
and maturation, where IL-21 promotes the generation of IgA plasmablasts. The best effect 
on IgA production is noted when both cytokines are present and acts synergistically [9, 10].
3. Mechanisms of autoinflammatory process
3.1. The inflammation as a process occurs at the following situations
• First—acute response of immune system to pathogens invading the tissue after breaking 
the natural defence e.g. epithelial cells layer of mucous membrane etc. This process is termi-
nated after elimination of pathogens with subsequent healing of damaged tissue process.
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• Second—prolonged response due to recurrent fever episodes, recurrent inflammasome 
formation and overproduction of pro-inflammatory cytokines mediated by innate immune 
system. Here it belongs to a wide range of periodic fever syndromes. Nowadays, it is sug-
gested, that Crohn’s disease, as the result of aberrant bacterial sensing, is fulfilling the cri-
teria of autoinflammatory process.
• Third—chronic inflammatory reactions with production of autoantibodies against tissue 
and/or cellular elements resulting with irreversible damage of cells, tissues and organs. 
This self-directed and sustained chronic inflammation is typical for autoimmunity, medi-
ated by adaptive immune system, immune complexes formation and complement activa-
tion [6, 11–13].
3.2. Inflammasome and innate immune system
The receptors of innate immunity components (cells) reacting with pathogen molecular pat-
terns are called—pathogen patterns recognition receptors (PRRs). PRRs are reacting with 
pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns 
(DAMPs). Within different types of PRRs, most important for inflammasome formation are 
ones from the nucleotide-binding domain leucine-rich repeat (NLRs) family. In human this 
family contains 22 genes, but the formation of inflammasomes (large protein complex) is asso-
ciated with NLRP3, NLRP1, NLRC4 and AIM2. Inflammasome is a mediator of autoactivation 
of Caspase-1 and that in turn leads to activation of IL-1b and IL-18 [6, 13]. The inflamma-
tory process with the inflammasome formation is associated with activation of neutrophils, 
monocytes and macrophages. Among the chronic inflammatory diseases of the gastrointes-
tinal tract, Crohn’s disease seems to be mediated by autoinflammatory than autoimmune 
pathomechanisms.
3.3. From autoinflammation to autoimmunity
The products of inflammasome such as IL-1β and IL-18 influence not only innate immune sys-
tem but also adaptive system, through activation of T and B lymphocytes. The up-regulation 
of IL-2 R (receptor for IL-2) expression on T cells, boosts of B cells–derived production of 
antibodies, supports prolonged survival of T and B lymphocytes. The other effects of these 
cytokines is acceleration of Th17 (by IL-1β) and Th1 (by IL-18), functional subpopulations 
of T cells, maturation [6]. The activity of overproduced cytokines in inflammasome bridges 
the innate and adaptive immunity system in reactions to pathogens. Apparently, there are 
some diseases with pathomechanisms of both types of chronic inflammatory reactions as a 
continuum from typical autoinflammatory to autoimmune disease. This hypothesis formed 
by Kastner [12] was based on shift of components of tissue infiltrations along the time of dis-
ease—during autoinflammatory stages, the majority of cells were—neutrophils, monocytes, 
macrophages and dendritic cells—smoothly transforming to infiltration typical for autoim-
mune process such as activated T and B lymphocytes producing typical profiles of cytokines, 
e.g. Th1, Th17 and autoantibodies [12].
Autoimmunity of Gastrointestinal Tract
http://dx.doi.org/10.5772/67281
75
4. Mechanisms of autoimmunity
4.1. Activity of immunocompetent cells and overproduction of cytokines
Mechanisms of supporting the self-tolerance are based on suppression of effector T lympho-
cytes proliferation and down-regulation of immune response [14]. The peripheral tolerance 
is regulated with different mechanisms, but a crucial role in maintaining this tolerance is 
played by regulatory T cells (Tregs). The dysfunction and/or decreased number of Tregs 
is associated with increased risk of autoimmunity, seen as a case in patients with humoral 
immunodeficiency (e.g. CVID), where more than 60% of patients demonstrate a low number 
of Tregs and co-existent autoimmune diseases such as diabetes mellitus type 1, systemic 
lupus erythematousus, celiac disease, thyroid diseases, etc. Naive Tregs are generated in 
thymus and transformed to inducible Treg (iTreg) in periphery, mainly in the gut. Tregs pro-
duce anti-inflammatory cytokines—TGF-β1, IL-10, IL-35 [14–16]. Immune response to patho-
gens includes differentiation of T lymphocytes into two functional subpopulations—T helper 
1 (Th1) producing pro-inflammatory cytokines and T helper 2 (Th2) producing anti-inflam-
matory cytokines. Additional subpopulations of T lymphocytes are Th17 cells releasing IL-17 
(IL-17A, IL-17F). The list of cytokines derived from cells involved in pathogens’ response is 
long, and among them, cytokines such as TNF and IL-22 also play an important role.
Activation of Th1 lymphocytes results in high level of IFN-γ and IL-2 and/or TNF. The Th1-
derived profile of cytokines supports inflammation and induces fever and infiltrations in 
target tissues. Intra-cellular bacterias and micobacterias are killed by macrophages activated 
with Th17-derived cytokines [16, 17]. Th2 subpopulation balances pro-inflammatory cytokines 
activity due to anti-inflammatory suppressing role of IL-4, IL-5 and IL-13 [14–16]. The profile 
of cytokines typical for given subpopulation of Th cells is not limited and Th2 are producing 
small amount of TNF and IL-2 with pro-inflammatory activity. Stimulation of B cells towards 
immunoglobulins class switching is also associated with Th2 cells [16]. Stimulated B lym-
phocytes produce specific antibodies either, differentiate into memory cells subpopulation or 
mature into plasmablast and long-life plasmocytes. In terms of autoimmunity B cell differen-
tiation and maturation is directed to autoantigens and result in autoantibodies production.
In last few years dysfunction of autophagy was declared a new crucial mechanism for develop-
ment of inflammatory bowel diseases. In physiology autophagy is one of cellular stress response 
indispensable for adaptation to starvation, degradation of aberrant proteins or organelles. 
Moreover, genes loci associated with increased risk for IBD are shared with genes required for 
autophagy, suggesting possibility of autophagy disorders in IBD. In mucous membrane function, 
the disorders of autophagy affect some aspects of innate and acquired inflammatory response, 
e.g. function of Paneth cells, cytokines production, pathogens clearance and, what was showed 
in last time, decrease function of goblet cells and absorptive function of microvilli [18, 19].
4.2. Production and role of autoantibodies
The natural antibodies of IgM class with moderate self-antigen affinity play first-line role in 
defence against pathogens. The autoantibodies showing high affinity to our own antigens are 
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IgG class and are concerned as pathologic, although they are detected in low titres in serum 
of healthy individuals [20]. The reaction of IgG autoantibodies with antigens, circulating in 
serum or present in tissue, forms complexes activating complement pathway. Complement 
activation mediating tissue damage is concerned in systemic autoimmune disease e.g. SLE, 
less expressed in organ-specific diseases, when antibodies react with target antigen presented 
in given organ e.g. thyroid, Langerhans islet or suprarenal gland cells, ovary cells and others. 
Beside the role in tissue damage process, the presence of autoantibodies is the marker of auto-
immune process and/or mechanism leading to clinical symptoms. Type and titre of antibodies 
circulating in serum support clinical diagnosis and help in differential diagnosis of overlap-
ping syndromes. Association of autoantibody levels with clinical course of disease is rare, but 
important for therapy adjustment e.g. dsDNA level in SLE. In systemic autoimmune diseases 
the role of B-1 subset of B lymphocytes in autoantibodies production was suggested due to 
high effectiveness of B-1 cells in presenting antigen process [20]. The long list of different 
types of autoantibodies reflects the long list of structures inducing antigen-dependent B cells 
response. Autoantibodies against nuclear proteins and organelles are believed to be a conse-
quence of exposing previously hidden antigens due to apoptosis, the presence of cell debris 
and disturbances of dying cell cleavage. The good example for cell debris serving as antigen 
is production of antibodies to cyclic citrullinated peptides (CCP) in rheumatoid arthritis as 
a result of acquired neoepitope after prolonged inflammation. The autoantibodies used as a 
marker of autoimmune disease are helpful in diagnosis in overt disease; however, they are 
present also in detectable traces in sera symptom-free patients’ family members, indicating 
a higher risk of autoimmune disease than that in general population. The careful monitoring 
is important to avoid not only overdiagnosis but also delay in diagnosis. Another problem 
is tied to sensitivity, specificity and frequency of autoantibodies—some of them are clini-
cally significant, but observed in minority of patients, in opposite to antibodies noted in high 
amount of patients, but with low specificity e.g. rheumatoid factor for rheumatoid arthritis.
In gastrointestinal tract autoantibodies are indicative for autoimmune gastritis, liver diseases, 
biliary tract pathologies, ulcerative colitis and celiac disease. According to definition and cri-
teria of autoimmune and autoinflammatory disease, Crohn’s disease is nowadays considered 
to be autoinflammatory syndrome due to activation of innate immune system and lack of 
autoantibodies production. The autoantibodies typical for gastrointestinal diseases are shown 
in Tables 1 and 2.
Diseases and autoantibodies to Assay Clinical significance and comments Comments
Celiac disease (CD)
Tissues transglutaminase ELISA Highly specific, quantitative assay, 
diagnosis and monitoring GFD
Significant in IgA class, IgG 
in isolated IgA deficiency
Reticulin (endomysial) IIF Qualitative assay
Atrophic gastritis (AIG)
Parietal cells (PCA) (antigen: H+/
K+ATPase)
IIF Specific for gastritis, quantitative 
assay is significant for diagnosis and 
monitoring
Often associated with 
thyroid autoimmunity
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Type of antibodies Patients Antigen Other comments
AIH type 1:
Antinuclear (ANA) 35–40% Chromatin, histones, centromere, 
dsDNA, ssDNA, ribonucleoprotein 
complexes
Non-specific for AIH, seen in 
other autoimmune diseases
Anti-smooth muscles (SMA) 85% Microfilaments, intermediate 
filaments-vimentin, desmin, 
polymerised F-actin
Subset of SMA, poor prognosis
Anti-actin
Perinuclear antineutrophil 
antibodies (pANCA)
100% Peripheral nuclear membrane 
components (pANNA), 
myeloperoxidase (pANCA)
pANNA specific for AIH-1 in 
absence of other antibodies
AIH type 2
Liver kidney microsomal 
(LKMA)
100% Cytochrome P4502D6 Present in HCV, CMV and HSV 
infections
Soluble liver antigen (SLA) 58–60% O-phosphoserine tRNA, SEC tRNA 
syntethase
Aggressive course, relapses, 
poor prognosis
Liver cytosol-1 (LC-1) 60% Formiminotransferase cyclodeaminase Rapid progress to cirrhosis
PBC
AMA2, 4, 8, 9 90–100% AMA 2-inner membrane
AMA 4- 8- 9-outer membrane of 
mitochondrium
Titre and type are not related to 
course of PBC
PSC
Perinuclear antineutrophil 
antibodies (pANCA)
90% Non-specific, often in patients 
with PSC and IBD
Table 2. Autoantibodies used for diagnosis of liver and biliary tract diseases. Acc. [34, 42, 44, 46, 59].
Diseases and autoantibodies to Assay Clinical significance and comments Comments
Intestine diseases (IBD)
Ulcerative colitis: goblet cells 
(anti-mucin)
IIF About 60% patients of UC, about 30% 
of Crohn’s disease
Differences between regions 
of large bowel
pANCA (anti-MPO) IIF About 80% of UC patients Present in PBC and AIH 
patients
Crohn’s disease:
ASCA ELISA
IIF
About 80% of Crohn’s patients Up to 25% in 1st degree 
relatives
Anti-pancreatic (PAB) (anti-acinar 
cells)
IIF About 30% of Crohn’s patients with 
disease localized in proximal jejunum
High specificity but low 
frequency
Table 1. Autoantibodies detected in serum patients with gastrointestinal disease, their clinical significance in diagnosis 
and differential diagnosis. Acc. [29, 33, 34, 38, 39, 43, 56].
Immunopathogenesis and Immune-based Therapy for Selected Autoimmune Disorders78
4.3. Tissue damage
In systemic autoimmune diseases, autoantibodies are playing role in tissue damage through 
formation of immune complexes activating classical complement cascade leading to mem-
brane attack complex (MAC) formation. Excluding celiac disease, the role of autoantibod-
ies in gut autoimmunity, is not fully understood, generally used as marker of process, then 
mechanism of tissue damage. Based on these observations, changes in tissue with irreversible 
damage might be described as three different components:
• First—infiltration of lymphocytes from deep crypt level to the top of villi. Flow cytometry 
and histochemistry analysis characterise these cells as T lymphocytes, activated T cells, B 
cells, plasmoblasts and plasmocytes locally producing autoantibodies. Number of intra-
epithelial lymphocytes (IEL) is high and infiltrating cells often formed secondary lymph 
nodules. Chronic inflammation is sustained by production of pro-inflammatory cytokines, 
and results in visible thickening of intestine wall.
• Second—presence of fibroblasts and progressing fibrotic process e.g. in liver leading to 
cirrhosis, in small and large ducts of biliary system leading to their walls thickening and 
narrowing the lumen and at the end their obstruction.
• Third—presence of other cells e.g. neutrophils, macrophages in infiltrations. These short 
living cells are dying within infiltrations in neighbourhood of hyper-activated adaptive 
immune system, what facilitates recognition of antigens and production of autoantibodies 
e.g. antinuclear, to myeloperoxidase (pANCA) and to others organelles. These cells pro-
duce various factors attracting new cells to come and support progression of infiltrations. 
They also produce variety of different trophic factors e.g.VEGF supporting neovasculari-
sation for better nutrition of cells forming increasing infiltrations and process of fibrosis. 
Neutrophils form microabscesses within intestinal wall and macroabscesses between intes-
tine loops [21–27].
Lymphocytes present in inflammation site under the epithelial layer are activated in sequen-
tial steps to develop and support chronic inflammation resulting in tissue damage. Initially, 
Th0 cells are activated and differentiate into different T lymphocytes functional subpopula-
tion—Th1 with stimulation of IL-12, IL-18; Th17 with stimulation of IL-6 and TGF-β and Th2 
with help of IL-4. IFN-γ and TNF, produced by Th1, activate macrophages and, in autocrine 
and paracrine mechanisms, stimulate further production of TNF. This activation is associ-
ated with induction of epithelial cells apoptosis and damage to first defending cellular bar-
rier. High level of TNF facilitates maturation of stromal cells into myofibroblasts releasing 
metalloproteinases—tissue degrading enzymes (MMPs). IL-17 produced by Th17 is respon-
sible for recruiting neutrophils into infiltrations during active inflammation. Even more 
complex and indirect is the role of IL-21, another cytokine produced by Th17, engaged in 
supporting of MMPs production followed by enterocyte apoptosis and basement membrane 
degradation [4]. In process of inflammatory infiltration formation, there is additional small 
subpopulation of cells with lymphocytic morphology, but without lineage determinants 
expression. These cells are called innate lymphoid cells (ILCs) and have ability to produce 
cytokines [17, 21].
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5. Genetic associations of celiac disease and inflammatory bowel diseases
Observations of familiar occurrence of celiac disease indicated genetic background associated 
with MHC determinants. Now, this background is defined as expression of HLA-DQ2 and/
or HLA-DQ8 in patients’ cells. Expression of one or both of these determinants in relatives of 
celiac disease patient suggests introduction of diagnostic procedures for atypical (latent, late-
onset) form of celiac disease [27–29]. In Crohn’s disease (CD) and ulcerative colitis (UC) the 
genetic background was unknown until discovery of variation of NOD2 gene and IL-23 recep-
tor gene. NOD2 is associated with severe, stricturing/penetrating course of Crohn’s disease 
thus helps in selecting patients for more aggressive therapy. Similar association is described 
for DRB1*0103 and severe clinical course of UC [30, 31]. The high number of susceptibility loci 
discovered in Crohn’s disease, now is described also for ulcerative colitis. The list of suscepti-
bility loci for CD and UC is shown in Table 3 with column list loci common for both diseases 
[30, 32]. The precise role of these loci in facilitation of development of autoimmune disease 
(UC) or autoinflammatory disease (CD) of gastrointestine tract is unknown. Although, the 
specific role of particular genes is known—genes NOD2, IIRGM, ATG16L1 in autophagy 
and innate immunity mediated processing of bacterias in autoinflammatory process, genes 
HNF4A, LAMB1, CDH1 in epithelial barrier function, see Table 3.
6. Serological diagnosis and monitoring of disease’s course
The autoantibodies and antibodies in serum are detected by using indirect immunofluores-
cence, ELISA technique, blotting technique and radioimmune assay (RIA). In indirect immu-
nofluorescence (IIF), the antibodies react with tissue sections and the results are visible as 
Susceptibility loci in Crohn’s disease Susceptibility loci common in Crohn’s 
and ulcerative colitis
Susceptibility loci in 
ulcerative colitis
Cellular innate immunity Th17 Epithelial barrier
NOD2, ATG16, IRGM, LRRK2 IL23R, IL12B, STAT3J, AK2, TYK2 ECM1, NHF4A, CDH1, 
LAMB1, GNA12
Immune-mediated Immune-mediated Immune-mediated
PTPN22, CCR6, IL2RA, IL18RAP, IL27, 
ERAP2, ITLN1, CCL2/CCL7, TNFSF11, 
BACH2, TAGAP, VAMP3
MST1, IL10, CARD9, REL, PRDM1, 
TNFSF15, ICOSLG, IL1R2, YDJC, 
SMAD3, PTPN2
INF□/IL26, IL8RA/IL8RB, 
IL2/IL21, IL7R, TNFRSF9, 
TNFRSF14, IRF5, LSP1
Other Other Other
DENNDIB, DNMT3A, GCKR, THADA, 
SP140, PRDX5, ZPF36L1, ZMIZ1, MUC1, 
CPEB4, FADS1, 5q31
NKX2-3, CREM, C11Orf30, ORMDL3, 
RTEL1, PTGER4, KIF21B, CDKAL1, 
ZNF365
OTUD3/PLA2G2E, DAP, 
PIM3, CAPN10
HLA
DRB*103
Table 3. List of susceptibility loci for inflammatory chronic disease of small (Crohn’s disease) and large intestine (ulcerative 
colitis). Acc. [19, 30].
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fluorescence of indicator tissue or cell structure (e.g. nucleus, nucleolus, centromeres, nucleus 
membrane proteins) after reaction with antibody. IIF helps to answer if the antibodies are 
present in patient’s serum and what is an antigen. Semiquantitative IIF indicating titre of 
antibodies is based on patient’s serum dilution to end-titre of positive reaction and compari-
son to end-titre of control serum. In case of antinuclear antibodies presence in serum, IIF is an 
initial step for making diagnosis. Positive result of IIF assay (end-titre higher than control) is 
followed by ELISA (enzyme-linked immunosorbent assay) or blotting test with eluated, pre-
cisely described antigen, e.g. dsDNA, SS-A, SS-B, Jo-1 and others associated with particular 
autoimmune disease, e.g. SLE, systemic sclerosis, polymyositis, neonate lupus. IIF is still used 
for detection of parietal cells, goblet cells antibodies, pANCA, anti-mitochondrial, LKMA and 
anti-smooth muscles antibodies. In ELISA, results are quantitative based on colorimetric reac-
tion with enzyme substrate. ELISA is used for detection of antibodies to tissue transgluta-
minase (TTG) in diagnosis and monitoring of celiac disease, ASCA in Crohn’s disease, SLA 
antibodies in AIH. Now, ASCA are selected from Saccharomyces cerevisiae membrane anti-
gens—laminaribiose, chitobiose, mannobioside, laminarin, chitin and are detected in ELISA 
tests. The blotting technique tests are used for anti-mitochondrial antibodies type 2,4,9, anti-
nuclear antibodies for eluated antigens detection. The RIA is last method used for antibodies 
detection based on counting of isotope radiation after reaction of autoantibodies with eluated 
antigen. This method is used for detection of antibodies circulating in low level, often below 
detection by above-mentioned methods, but still important for diagnosis or monitoring of 
disease. The typical use of RIA is detection of anti-TSH receptor antibodies in patients with 
thyroid diseases, autoantibodies in diabetes mellitus type 1 (GABA, insulin antibodies and 
others). RIA is not a common technique, because of the requirement of special isotopic labora-
tory. Detection of autoantibodies is generally used for diagnosis of autoimmune diseases in 
symptomatic individuals or in population with high risk of given disease and/or with unspe-
cific symptoms, e.g. growth below expected, underweight, chronic diarrhoea and others typi-
cal for celiac disease. Some of antibodies are used for monitoring of therapy results—TTG 
antibodies in celiac patients on gluten free diet (GFD), dsDNA for SLE therapy, anti-TPO 
antibodies for Hashimoto disease on supplement therapy [33–46].
7. Microscopic diagnosis of inflammatory bowel diseases and celiac 
disease
Microscopic evaluation of mucous membrane in celiac disease, Crohn’s disease and ulcerative 
colitis showed infiltration containing immunocompetent cells with majority of lymphoid phe-
notype. Biopsy is indicated for staging of villi damage in classic and atypical celiac disease, 
description of cellular infiltrations in Crohn’s disease and ulcerative colitis. In liver diseases 
biopsy is essential for diagnosis and monitoring the progress of fibrosis changes leading to cir-
rhosis. Biopsy is usually taken during endoscopy of the upper and lower gastrointestinal tract 
from different parts of intestine, in majority cases from places with visible macroscopic changes. 
In many cases, biopsy specimens taken from normally looking mucous membrane showed the 
microscopic changes (infiltrations with lymphocytes and neutrophils, increased number of EIL 
and other), what suggested occurrence of chronic subclinical inflammatory process [24–27, 31].
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8. Clinical symptoms of autoimmune diseases of gastrointestinal tract
8.1. Celiac disease
Classical celiac disease is observed in small children after introduction of gliadin, secalin or 
hordein (components of gluten) in diet. Typical symptoms include chronic diarrhoea, inhibi-
tion of weight gain or weight loss, abdominal pain, recurrent aphthous, changes in behav-
iour—‘negativity’, (“mister/miss no”). In delay of diagnosis the inhibition of growth, changes 
in enamel, low protein level lead to muscles atrophy confirmed inadequate absorption. 
Nowadays, this typical clinical picture is noted in no more than 15% of patients with geneti-
cally proved diagnosed celiac disease. Celiac disease may be diagnosed in any age, even in 
people after 50 years old. This celiac disease diagnosed later than in small children is called—
latent, atypical or silent. Symptoms seen in adults are different than observed in small chil-
dren. More often there are effects of defective absorption such as—anaemia due to iron 
deficiency, osteopenia/osteoporosis, enamel defects, aphts, (aphthous stomatitis), feeling of 
malaise chronic or intermittent diarrhoea, but also constipation, abdominal pain, discomfort, 
vomitus. Celiac disease is often associated with other autoimmune disease e.g. diabetes melli-
tus type 1, autoimmune thyroid diseases, autoimmune liver disease, autoimmune thrombocy-
topenia (mainly chronic), autoimmune Addison’s disease. Moreover, celiac disease occurred 
about 20 times more frequently, in children with isolated IgA deficiency, CVID with low level 
of IgA and in about 80% of patients with dermatitis herpetiformis. Untreated celiac disease in 
young adults leads to unexplained subfertility, recurrent miscarriages, increasing the risk of 
lymphoma and gastric/large bowel carcinoma. The therapy is based on restricted gluten-free 
diet (GFD) [26–29, 47–50]. In humoral immunodeficiency, in about 5% of patients, the celiac 
disease is refractory to GFD. In refractory celiac disease (RCD), all clinical symptoms such as 
progressing malabsorption causing inhibition of growth, loss of weight, undernourishing, 
low level of vitamins, iron and proteins are observed. Moreover, introduction of immunosup-
pressive therapy resolves symptoms transiently or even. Patients required enteral or total 
parietal nutrition (TPN) for long time as supportive therapy. The use of monoclonal antibod-
ies against TNF and/or IL-6, different combinations of immunosuppressive drugs result in 
partial and terminal remission in majority of patients. These patients are candidates for HSCT, 
even in poor clinical condition, because only this therapy offers possibility to cure the disease 
and save their life [51]. As alternative to HSCT from unrelated donor, autoHSCT was used 
for such patients with success in five out of eight patients with five-year survival in 66% [52].
8.2. Crohn’s disease
Crohn’s disease is lifelong disease with symptoms of chronic inflammation mediated by immune 
system. Like in other chronic inflammatory diseases, the inducing factor is unknown, but it 
is believed, that interaction between genetic background and environmental factors, mainly 
intestinal microbiota, leads to the disease. In last 20 years two tendencies are noted: increased 
number of patients and decrease in age, so children before age of 2 years fulfilling the criteria 
of CD are observed [19, 25, 31, 53]. The clinical symptoms are very heterogeneous, due to local-
ization of inflammation in any part of gastrointestinal tract from mouth to anus, age of patient, 
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time of process before onset [19]. Moreover, in many patients symptoms from gastrointestinal 
tract are mild or unspecific, but extra-intestinal symptoms signal chronic disease. The perianal 
abscesses, recurrent aphthous stomatitis, fistulas, anal fissures, joints pain are noted before typi-
cal gastrointestinal symptoms like chronic or intermittens diarrhoea, pain, blood in stool and 
others. In young children very often the acute stage of disease is severe followed by aggressive 
course. Disease activity is grading as mild (Crohn’s disease activity index—CDAI—150–220), 
moderate (CDAI—220–450) and severe (CDAI >450) [25]. Therapy is adjusted to symptoms 
and grading of disease at diagnosis. The antibodies to saccharomyces cerevisiae (ASCA) in IgA 
(and/or IgG class) are detected in high level what suggests increased intestinal barrier perme-
ability and contact of microbiota with immunocompetent cells [19, 21, 22, 53]. Autoantibodies to 
acinar pancreatic cells are noted in patients with CD localized in proximal jejunum. However, 
the percentage of patients demonstrating these antibodies is low (about 30%), so there are not 
useful for diagnosis of CD. ASCA antibodies are not correlated with grading and course of dis-
ease, although, during the remission, level of ASCA is lower than in acute stage. The criterion 
of remission is resolving clinical symptoms up to CDAI <150 and maintenance at least for 12 
months. The course of CD is unpredictable, so the remission maybe long lasting, short with 
relapses or chronic disease without remission. Localized disease limited to ileocaecal region 
only, may change into extensive disease affecting other regions in more than 100 cm in extent. In 
majority of patient response to steroids is very good with long remission, but in some patients, 
steroid-dependent form of disease or steroid-resistant form are observed. In both situations risk 
of accumulative side effects of steroids is high limiting prolong use of steroids, indicating intro-
duction of second line therapy. Relapse is recognised, when symptoms are recurrent indepen-
dently from therapy-maintaining remission. Diagnosis and monitoring of therapy is based on 
macroscopic and microscopic detection of features typical for CD. Biopsies during endoscopy 
are taken from involved and uninvolved areas for examination of focal or chronic inflamma-
tion, lymphocytic infiltrations, crypt irregularity, granulomas, irregular architecture of villi and 
other features typical for CD. In remission, biopsies from similar areas show healing of inflam-
mation in different stages [25]. Introduction of monoclonal antibodies against TNF into therapy 
of CD revolutionised the therapy and medical care of CD patients, with improvement of long 
remission rate, comfort of live and survival of CD patients [31, 53].
8.3. Ulcerative colitis
Ulcerative colitis (UC) is a chronic inflammatory process localised exclusively in large bowel 
affected mucous in continuum. The course of disease is remitting and relapsing like Crohn’s 
disease. The problem of precise diagnosis is in cases with Crohn’s disease localised in large 
bowel overlapping clinical symptoms. Clinical symptoms in typical case of UC are associated 
with chronic diarrhoea, blood and mucin in stools, rectal bleeding, abdominal pain, cramps, 
feeling of rectal urgency and many others. The extra-intestinal symptoms are rare, present in 
about 10% patients with UC, as arthropathy, erythema nodosum preceding onset of typical 
symptoms from large bowel. In serum antibodies to pANCA are seen in about 80% of patients 
with typical clinical symptoms. Multiple biopsy of mucous membrane usually supports the 
clinical diagnosis of UC and helps in discrimination between Crohn’s disease localized in 
large bowel and UC. Microscopic features are divided into—architectural changes, epithelial 
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abnormalities and inflammatory features. Architectural features included crypt branching, 
crypt distortion, atrophy and surface irregularity. Epithelial cell abnormalities are—mucin 
depletion, metaplasia of Paneth cells. Inflammation is associated with infiltration lamina pro-
pria with lymphocytes, plasma cells and neutrophils, aggregates of lymphoid cells, in number 
of patients in lamina propria are numerous eosinophilic neutrophils. Cellular infiltrations are 
diffusive and transmucosal. Neutrophils migrating through crypts’ epithelium are producing 
crypts’ disruption and abscesses resulting in cell damage. Moreover, the stromal changes are 
associated with diffuse thickening of muscularis mucosa noted in patients with longstanding 
active disease or quiescent form of UC. Grading of UC is similar to Crohn’s disease as mild, 
moderate and severe based on number of bloody stools, temperature, pulse, CRP and anae-
mia as result of mucous bleeding. In remission the lesions of large bowel mucous are healed 
and clinical symptoms resolved. Relapses are rare or frequent, in some patients are continu-
ous without clinical and histological remission [24]. Like Crohn’s disease patients are steroid-
dependent or steroid-refractory, what means that therapy with steroids is not effective or 
effective only with high dose of steroids with risk of accumulation of side effects. Reduction of 
steroids dose resulted in recurrent active disease. Despite of steroid in first line 5-aminosalicy-
lites are used but in patients with UC classified as moderate grade of disease activity. The sec-
ond line of therapy included 6-mercaptopurine or azathioprine with good results in majority 
of patients. Good response to azathioprine or 6-mercaptopurine is associated with reduction 
of steroid dose what helps to avoid accumulation of side effects. Resistance to immunosup-
pressive therapy is indication for surgery or for biological therapy. Use of anti-TNF monoclo-
nal antibodies gave remission in about 30% of patients. Monoclonal antibodies are used very 
often after surgery to prevent or reducing postoperative relapses. However, use of mono-
clonal antibodies, immunosuppressive therapy the rates of surgery in UC have not changed 
significantly [24, 54, 55]. Monoclonal antibodies used in therapy of UC are shown in Table 4.
8.4. Atrophic gastritis
Antibodies to parietal cells (PCA) are typical for autoimmune chronic gastritis (AIG) associ-
ated with megaloblastic anaemia in consequence of wit B12 and intrinsic factor low level due 
to disturbances of gastric mucous function. AIG suggested from clinical symptoms after dem-
onstration of antibodies should be proven with gastroscopy and histological assay of mucous. 
Biopsy of gastric mucous is important for diagnosis of gastric cancer and premalignant stages. 
This wide diagnosis is important, due to prevalence of AIG in men. AIG is a progressing dis-
ease with atrophy of mucous membrane of corpus and fundus of stomach. AIG is very often 
noted as associated disease of thyroid autoimmune disease, diabetes type 1 in poliendocrine 
syndromes. In therapy, besides diet and parasols, vitamin B12 and intrinsic factor are admin-
istered parenterally with good effect in majority of patients [56, 57].
8.5. Primary biliary cirrhosis
Primary biliary cirrhosis (PBC) was the first autoimmune disease associated with jaun-
dice and liver cirrhosis with autoantibodies in serum significant for differential diagnosis 
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of autoimmune overlapping liver diseases. The anti-mitochondrial antibodies (AMA) are 
noted only in this type of biliary tract autoimmune diseases. There are typical for this type 
of cholangitis significant for serological diagnosis of PBC and differential diagnosis of over-
lapping autoimmune liver diseases [36, 58, 59]. Now, depending of antigens coming from 
different elements of mitochondria 9 types of AMA are described, but only AMA2, AMA4, 
AMA8 and AMA9 are specific for PBC and used for serological diagnosis [35, 44, 46]. ELISA 
technique is used for quantitative assay of AMA, but the amount of AMA is not associated 
with severity of symptoms and clinical course. Practically, it is enough to detect AMA2 in 
the serum to suggest the diagnosis of PBC [35, 59]. The study of association between MHC 
determinant and autoimmune disease showed the association of PBC with determinants: 
HLA-DR8, HLA-DR11 and HLA-DR13 in part of patients [59]. The inflammation and fibrotic 
process is progressing leading to cholestasis, portal fibrosis, liver cirrhosis and failure as 
end-stage of disease. Histological studies of biopsy showed 4 stages of PBC from portal 
inflammation (stage 1), through peri-portal fibrotic changes (stage 2) and bridging fibrosis 
(stage 3) up to symptomatic cirrhosis (stage 4) [59]. The clinical symptoms are unspecific for 
long time with the cholestasis as symptom of biliary ducts failure due to fibrosis followed 
by liver cirrhosis.
Target Monoclonal antibody Disease
TNF Infliximab, Golimumab CD, UC, RCD
Adalimumab, Humira CD, UC, RCD
Certolizumab pegol CD
Etanercept CD
α4-integrin Natalizumab CD, UC
α4β7-integrin Vedolizumab, Abrilumab CD, UC
IL-12/IL-23 Ustekinumab, Briakinumab CD
IFN-γ Fontolizumab CD
IL-6 receptor Tocilizumab CD
IL-2 receptor Daclizumab UC
CTLA-4 Abatacept CD, UC
CD20 Rituximab CD, UC, RCD
JAK1,2,3 Tofacitinib CD
Tyrosine kinase receptor Masitinib CD
Anti-sense ICAM-1 inhibitor Alicaforsen CD
Note: CD, Crohn’s disease; UC, ulcerative colitis; RCD, refractory celiac disease.
Table 4. Monoclonal antibodies used in therapy of autoimmune and autoinflammatory diseases of gastrointestinal tract 
and liver. Acc. [53].
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8.6. Primary sclerosing cholangitis and autoimmune sclerosing cholangitis
The primary sclerosing cholangitis (PSC) and autoimmune sclerosing cholangitis (ASC) 
belong to group of biliary ducts inflammation overlapping with chronic hepatitis leading to 
cirrhosis. HLA-DR1 and HLA-DQ1 are often noted within patients with PSC [59]. In these 
diseases the anti-mitochondrial antibodies (AMA) are absent; however, the other antibodies 
(pANCA) are present in 60–90% of patients [46]. These antibodies are not specific for PSC, 
but are supporting autoimmune mechanism in PSC. The histological changes are noted in 
intra-hepatic and extra-hepatic biliary ducts involving small and large ducts [58]. Diffused 
inflammation followed with fibrosis of biliary ducts is steroid resistant in majority of patients 
[36]. The development of PSC and ASC is insidious and symptomless upon the moment of 
onset of jaundice. Patients are claiming unspecific symptoms like abdominal pain (upper 
right quandrant), feeling fatigue and malaise, sometimes—pruritus. PSC is a disease associ-
ated with autoimmune hepatitis but very often is a co-existent disease in ulcerative colitis 
and other chronic inflammatory bowel diseases. Another association of PSC is IgG4-related 
disease; rare clinical symptoms present in different organs, including e.g. pancreas inflam-
mation. The immunological assays show high level of IgG4 subclass of IgG what is critical 
for diagnosis of basic disease. The stenosis and fibrotic changes in biliary ducts extra- and 
intra-hepatic, changes in liver hilar are similar to PSC and ASC. However, in IgG4-related 
disease the therapy based on steroids is effective, what helps to differentiate from other forms 
of sclerosing cholangitis [41, 45, 58–60].
8.7. Autoimmune hepatitis
Autoimmune hepatitis (AIH), chronic liver inflammation is described as AIH type-1 and AIH 
type-2 based on profile of autoantibodies, time of onset and response to therapy. Aetiology 
of autoimmune hepatitis, like other autoimmune diseases, is unknown. Moreover, the pre-
cise role of autoantibodies in given types of hepatitis, relations between types of antibodies 
(e.g. combination ANA/SMA), pathomechanisms leading to good response or resistance to 
therapy and aggressiveness of course are far from description. AIH type 1 is specified by 
antinuclear (ANA), anti-smooth muscles (SMA) and anti-actin antibodies. In type 2 antibodies 
to liver microsomal antigen (LKMA-1) and liver cells cytosol antigens (LC-1) are significant. 
AIH type-1 is more frequent (>80%) than AIH type-2, observed in young people (majority of 
patients in age below 30 years) with very good response to therapy (mostly steroids). AIH 
type-2 is frequently noted in children with more aggressive course, resistance to therapy with 
cirrhosis in about 80% of patients. The serological diagnosis is clinical significant for the esti-
mation of therapy strategy and prognosis for patient. Some of antibodies are related to course 
of disease and response to therapy, e.g. anti-actin antibodies are associated with higher fre-
quency of liver failure and patients’ death, suggesting liver transplantation as life-saving pro-
cedure [59]. The presence of different profile of antibodies are seen in overlapping syndromes 
e.g. AIH and sclerosing cholangitis—ASC and hepatitis associated with viral infection e.g. in 
HCV. Difference between AIH and HCV with autoantibodies—ANA, SMA and LKMA—is 
histological—in HCV the tissue infiltrations containing plasma cells are absent. The occur-
rence of LKMA in HCV is probably the result of molecular mimicry of cytochrome 4502D6 
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and viral genome [46]. Another typical combination of autoimmune diseases involving liver 
is AIH and PBC resembled by presence of pANCA and AMA simultaneously. However, lon-
gitudinal study did not show the poorer prognosis of AIH patients with AMA compared to 
AIH patients without AMA in serum [46]. The combination of AIH and sclerosing cholangitis 
is sometimes classified as autoimmune sclerosing cholangitis—ASC [61].
Antibodies seen in AIH-1, AIH-2 and PBC are shown in Table 2.
8.8. Other diseases: autoimmune enteropathy
Autoimmune enteropathy (AE) is a rare disease noted in infants and young children. Clinical 
symptoms included severe and protracted diarrhoea followed with weight loss, malabsorp-
tion syndrome. Pathomechanism is typical for autoimmune disease with the central role of 
anti-epithelial antibodies. Expression of HLA class II determinants on the surface of epithe-
lial cells in case of AE is facilitating recognition of autoantigen and stimulation of immune 
response with activated CD4 T lymphocytes [61]. Role of HLA class II determinants in AE 
was supported by observation of aberrant expression on epithelial cell from the crypts and 
overexpression by enterocytes suggesting local induction of autoimmune reaction with acti-
vation of intestinal T lymphocytes [62]. Clinical symptoms of AE are associated with autoim-
mune process against other organs and tissues. Besides autoantibodies against enterocytes, 
in AE antibodies toward gastric parietal cells, pancreatic islets cells, insulin, GADA, goblet 
cells, smooth muscles antigens, thyroid are noted. Combination of AE symptoms with auto-
immune polyendocrinopathy and skin manifestation is observed in IPEX syndrome [62, 63]. 
In biopsy of jejunum severe villi atrophy, inflammatory infiltrations with destruction of crypt 
structure and depletion of goblet cells (in cases with anti-goblet cells antibodies) are observed. 
In majority of patients increased apoptosis of epithelial crypts is seen as typical feature [63]. 
Inflammatory changes are noted not only in jejunum, but in large bowel and stomach also, 
what indicate diffuse autoimmune disorder more difficult to control and release symptoms. 
Management of these patients include immunosuppression (e.g., steroids, azathioprine, 
cyclosporine, tacrolimus, MMF) and adequate nutritional support with correction of malab-
sorption effects, e.g., vitamins, calcium, proteins deficiency [62, 63]. In patients with poor 
response to therapy, monoclonal antibodies to TNF and immunoglobulins in high dose were 
introduced, but without breathtaking results. The good results on monotherapy were noted 
with cyclophosphamide [62].
9. Therapy of autoimmune diseases of gastrointestinal tract
9.1. Microbiota correction and diet
The use of selected bacterias for modification of dysbiosis in inflammatory bowel diseases is 
known from 1907 when consumption of fermented milk products containing Lactobacillus 
bulgaricus were used and associated with ‘longevity and good health’ [64]. Now, three dif-
ferent preparations are used—probiotics means live microorganisms with beneficial effect 
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on host health when administered in adequate amount, prebiotics defined as selectively 
fermented ingredient that allows changes in composition and/or activity in gastrointestinal 
microflora and the last—synbiotics when probiotics and prebiotics are used simultaneously 
[64]. List of probiotics contains different strains of Lactobacillus, e.g., casei, rhamnosus, gas-
seri, Bifidobacterium, Saccharomyces boulardii and others. List of prebiotics is shorter and 
contains inulin, xylooligosaccharide, oligofructose and fructooligosaccharide [64, 65]. Results 
of probiotics, synbiotics therapy are noted as mildering course of disease (e.g., ulcerative coli-
tis), than clinical remission or real corrections of dysbiosis [64, 65]. The effects and mecha-
nisms of used probiotic activity in patients with IBD are shown in Table 5.
Faecal microbial transplantation (FMT) is now a new approach to chronic microbial dysbiosis. 
The idea is to reintroduce and re-establish stable physiological bacterias from healthy donor 
supplanting dysbiotic microbiota. The first recognised successful use of this therapy was 
noted in patients with Clostridium difficile infection and dysbiosis in follow. In 2 weeks and 
1 month after this procedure the composition of faecal bacterial containing bacterias derived 
mainly from donor. In spectrum of gastrointestinal disease, it seems that correction of micro-
biota homeostasis is indicated in Crohn's disease. According to observations and hypothesis 
about the role of microbial homeostasis, the bacterial dysbiosis noted in Crohn's disease is 
common and associated with severity of symptoms. The correction of microbiota homeostasis 
in these patients leads to resolving of some symptoms and help in normalisation of jejunal 
function [64, 66].
9.2. Classical immunosuppression
Steroids were first in autoimmune diseases therapy and up to now, there are common as first 
line treatment. In refractory celiac disease, autoimmune liver and biliary tract disease and IBD 
steroids are used to release syndromes in acute stage of disease and as maintenance therapy 
in remission. In CD remission was obtained with steroid in about 80% of patients in first 30 
Antimicrobial effects Enhancement of mucous 
membrane integrity
Immune modulation
Alterations in intra-intestinal environment, 
production antimicrobial molecules, 
inhibits of pathogen adhesion and cellular 
invasion, antitoxin effects
Increase mucous production, 
better epithelial barrier, changes in 
surface proteins
Decrease of pro-inflammatory 
cytokine production, increase 
of anti-inflammatory cytokines 
production, induction of Treg cells, 
effect on B lymphocytes
Decrease of pH in intestine lumen, 
production of bacteriocins, defensins, 
competition for adhesion sites, production 
of antitoxins, prevention of toxin expression
Increase function of tight junction, 
secretion of water and chloride
Reduction of apoptosis mediated 
by TNF, increase of IL-10 
production, increase of secretion of 
IgA and production of antibodies
Prevention of Clostridium difficile 
infection, prevention of antibiotic-driven 
diarrhoea
Influence on cell-to-cell 
interaction, cellular stability, 
enhancement of epithelial cells
Prevention of antibiotic-driven 
diarrhoea, prevention of infectious 
diarrhoea, prevention of cancer
Table 5. Biological effects of probiotic, pre-biotic and synbiotic activity. Acc. [65].
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days of therapy [55]. Decrease of steroids dose, due to accumulation of side effects, is pos-
sible, when azathioprine or other classical immunosuppressant is added to therapy. Steroids 
are used as systemic with risk of accumulative side effects or enteral active budesonide acting 
in intestinal lumen with low absorption [55]. In CD, at the beginning of therapy, antibiotics 
were used very often, as in UC—5-aminosalicylates. Classical immunosuppression included 
azathioprine, methotrexate, cyclosporine A, tacrolimus and others. In children, in CD therapy, 
good results are obtained with cyclosporine A, but severe side effects are very often the limita-
tion of therapy. Prolong therapy with immunosuppressant in children is resulting with inhibi-
tion of growth, puberty, cytopenias (leukopenia, neutropenia, thrombocytopenia, anaemia) 
and list of steroids side effects—osteopenia/osteoporosis, obesity, diabetes. Another limitation 
is long perspective of therapy, so accumulation of side effects is serious problem, especially 
for children. In UC classical immunosuppression is less effective than in CD. However, good 
results in UC were noted, when tacrolimus (calcineurin inhibitor) was used in therapy sched-
ule. The target for tacrolimus and cyclosporine A is inhibition of TCR signalling, what resulted 
in blocking of T cell activation [14]. However, explanation why cyclosporine A is associated 
with good effects in CD, in opposite to UC when similar effects are obtained with tacrolimus 
is unknown. It maybe, that different profile of cytokines produced by given subpopulation of 
T lymphocytes mediating process of autoimmunity is a background for these observations. In 
autoimmune liver diseases steroids are used in first line of therapy together with azathioprine 
to reduce steroids dose and avoid side effects. In majority of AIH patients the response to this 
therapy in good (in about 90% of patients level of serum immunoglobulins and liver enzymes 
decreased to normal value). However, relapses are noted in 50–86% of patients within 6 
months of remission. For these patients the second line of therapy is advice—cyclosporine A, 
tacrolimus, mycophenolate mofetil with success in majority of AIH patients [59].
9.3. Biological therapy
The use of monoclonal antibodies is indicated as second line of therapy after poor response 
to steroids and classical immunosuppression. Celiac disease is included into diseases treated 
with monoclonal antibodies only in the case of GFD resistance and progression of malabsorp-
tion syndrome [28, 52]. The good effect of elimination of TNF is noted only in refractory celiac 
disease type 1. In refractory celiac disease type 2 with T lymphocytes responsible for process 
and resistance to immunosuppressive therapy, infliximab is not effective. For these patients, 
only HSCT procedure is curative [28].
A discovery of the crucial role of TNF in regulation of pro-inflammatory cytokines produc-
tion and supporting of inflammation was based on the idea of elimination of this cytokine as 
possible therapy. After good results observed in rheumatoid arthritis, ankylosis spondylitis 
patients, IBD was the next group of autoimmune diseases with successful anti-TNF therapy. In 
CD, anti-TNF therapy was used in refractory fistula sign form leading to surgery and disability 
of patients. Now, anti-TNF therapy is used in all patients with CD with indications for biologi-
cal therapy, e.g. steroid refractory or steroid dependent form of disease, acute stage with severe 
clinical symptoms, even life-threatening, lack of remission with chronic, stable symptoms of 
disease. In children with CD, anti-TNF therapy is used early in disease course, often in active, 
severe stage, without prolonged immunosuppressive therapy carrying high risk of side effects 
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for these patients [54, 55]. Proposition of sequential (step-by-step) therapy of CD included 
antibiotics and budesonide in first line, steroids and classical immunosuppression (azathio-
prine, methotrexate, 6-mercaptopurine) as second line and biological therapy as last line. This 
step-up therapy schedule maybe used as step-down after success with biological therapy, in 
maintaining of clinical remission. The effect of monoclonal antibodies is better, when anti-TNF 
antibody is used with other therapeutic, e.g., azathioprine [55]. Infliximab as anti-TNF therapy 
was introduced into schedule of UC therapy in 2005 year after good results of anti-TNF therapy 
in CD since 1998 year. Similar to CD, in UC monoclonal antibodies are used as last, third line 
of therapy after steroids and immunosuppression [54, 55]. In CD and UC as chronic diseases, 
anti-TNF therapy, like other therapy schedules, should be individualised (‘patient tailored 
therapy’). The choice of anti-TNF antibody from, e.g., infliximab to adalimumab depends on 
expected effects on given symptoms of patient. The lack of effect or severe side effects contra-
indicated continuing therapy suggests use of monoclonal antibody against other mediator of 
autoimmune process, e.g., natalizumab [54]. Natalizumab is recombinant, humanised IgG4 
monoclonal antibodies to α4-integrin with function of blocking this integrin. In consequence 
the migration of leukocytes into the intestine wall from blood is inhibited. Effect of this inhibi-
tion is noted as increase of leukocytes number in peripheral blood due to block of adhesion and 
transmigration out [54]. However, the fatal progressive multifocal leukoencephalopathy (PML) 
after natalizumab in three patients was concerned as severe side effects followed by withdraw-
ing of this antibody from the market. Now, natalizumab is available, but for patients without 
other possible effective therapy [54]. Vedolizumab is used in CD and UC, but the effects of 
therapy are rather low. Summarising vedolizumab use is indicated in moderate-severe CD, not 
for UC [53]. Briakinumab was very effective in rheumatoid arthritis but without good results 
in CD patients. Ustekinumab as inhibitor of p40 subunit blocking IL-12 and IL-23 prevent-
ing activation of Th1, Th17 and APC (antigen presenting cells) was used with success in CD 
patients after anti-TNF therapy without good effect. Moreover, this antibody helps in heal-
ing of perianal symptoms of CD. Other antibodies (anti-IL-13—Dectrekumab, anti JAK inhibi-
tors—Tofacitinib, anti-IL-6—Tocilizumab) are under clinical trials and pilot studies [53].
New promising biological therapies are directed against different molecules, including cyto-
kines produced by autoreactive T lymphocytes mediating chronic inflammation. Monoclonal 
antibodies against interleukins, interleukins receptors, integrins, IFN are used in different clin-
ical trials in CD and UC [54]. List of antibodies used in biological therapy is shown in Table 4.
9.4. Haematopoietic stem cell transplantation procedure
In celiac disease and IBD indications of HSCT procedure are associated with co-existent dis-
ease, e.g., haematological or severe course, resistant to therapy or diet with progression of 
malabsorption syndrome. Decision of HSCT is difficult, because patients resistant to ther-
apy with progress of disease, are usually on total parietal nutrition, with recurrent, prolong 
or opportunistic infections, malabsorption syndrome with high risk of death after HSCT 
procedure. Another therapy proposed is mesenchymal cell application (MSC)—used intra-
peritoneally, intravenously. However, the results are not conclusive, although a decrease of 
pro-inflammatory cytokines in mucous biopsy was noted [51, 52].
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10. Conclusions
Certain gastrointestinal tract diseases are classified as autoinflammatory/autoimmune due 
to chronic course with remissions and exacerbations, histological and serological features, 
good response to immunosuppressive treatment. Therapy is based on inhibition of immune 
system activation, reduction of inflammatory process, decrease of antibody production and 
complexes formation. Steroids are commonly used to obtain and, in small doses, to maintain 
remission. However, severe side effects or steroid resistance implicate the usage of classical 
immunosuppressive drugs. Classification of gastrointestinal tract diseases as autoimmune 
opened the opportunity for analogical treatment with other autoimmune diseases including 
monoclonal antibodies. Moreover, for progressive cases with poor prognosis haematopoietic 
stem cell, transplantation is proposed with encouraging results.
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